What is an autologous stem cell transplant?

An autologous transplant uses your own healthy stem cells after a high-dose chemotherapy reboot of the immune system. It is more like a specialized blood transfusion than a surgery. The aim is the deepest, longest-lasting remission possible.

Who can have a transplant?

Eligibility is based on overall health, fitness, and organ function, not just your age. Fit patients up to 70, and sometimes older adults in good shape, are routinely considered. Kidney impairment, including dialysis, does not automatically rule you out. Severe advanced heart or lung disease or an active infection is usually why a transplant is advised against.

How are stem cells collected?

After 3 to 6 cycles of initial treatment, ideally around cycle 4, you receive shots that move stem cells into the bloodstream. A machine then separates those cells from your blood over 3 to 4 hours across 1 to 5 days. Teams try to collect enough cells for one transplant and, if possible, a second course stored for later.

What happens during the transplant itself?

You receive high-dose melphalan to wipe out remaining myeloma cells, usually 200 mg per square meter, or 140 mg per square meter if the kidneys are severely impaired. One to two days later, your frozen stem cells are thawed and given back through an IV. They settle in the bone marrow over about 2 weeks, a process called engraftment.

How long does recovery take?

You typically spend 2 to 3 weeks in the hospital or clinic because your immune system is temporarily wiped out. Significant fatigue for 1 to 3 months is normal, and many people take 3 to 6 months off work. Inactivated vaccines, including mRNA COVID-19 shots starting about 3 months later, are restarted during recovery.

What if I am not eligible for a transplant?

You can skip the transplant and continue first-line therapy for a longer stretch, such as about 9 cycles of daratumumab with bortezomib, lenalidomide, and dexamethasone. Older or frailer patients may use a gentler combination of daratumumab, lenalidomide, and dexamethasone. After that, a daily maintenance pill is used to keep the myeloma asleep.

Back to Guidelines

First-Line Treatment

Autologous Stem Cell Transplant

Name: Autologous Stem Cell Transplant | CMDN
Creator: CMDN Editorial Team
Published: 2026-07-30

A Powerful Tool for Deep Remission

Medical Disclaimer: The following content is compiled based on the latest authoritative guidelines at home and abroad. It is for reference only for patients and their families and cannot replace the professional medical advice of the attending physician. Please be sure to follow the doctor's advice for the treatment plan.

Core Conclusion

Autologous stem cell transplantation (ASCT) using high-dose melphalan (200 mg/m²) and re-infusion of ≥ 2 × 10⁶ CD34+ stem cells/kg delivers complete response rates exceeding 50% to 70% and remains the first-line consolidation standard for fit patients up to age 70.

Detailed Points

(1) Who goes on this journey? (Indications & Age Limits) Your eligibility for a transplant is based on your overall health, fitness, and organ function, not just the year you were born. While clinical trials used to routinely exclude patients over 65, doctors today routinely consider fit patients up to 70 years of age, and sometimes even older adults who are in good shape. Even if you have kidney impairment—including being on dialysis—you can still be a great candidate for ASCT. Typically, only patients with severe, advanced cardiopulmonary disease or active infections are advised against it.
(2) Gathering your "seeds" (Mobilization and Apheresis) After 3 to 6 cycles of your initial medication (ideally around cycle 4), your team will collect your healthy stem cells before the medications tire out your bone marrow. You will receive injections (like Neupogen, Neulasta, or Mozobil) to "mobilize" your stem cells, encouraging them to move out of your bone marrow and into your bloodstream. Next, you will sit comfortably while a special machine separates these stem cells from your blood and returns the rest of your blood to you—a process called apheresis. This outpatient procedure usually takes 3 to 4 hours over the course of 1 to 5 days. The goal is to collect a minimum of $2 \times 10^6$ CD34+ cells per kilogram of your body weight for one transplant, but doctors ideally aim to collect at least $5 \times 10^6$ cells so you have enough saved in the freezer for two transplants, just in case you need them in the future.
(3) The "Deep Clean" (High-Dose Melphalan) When you are ready for the transplant, you will receive a powerful dose of a chemotherapy drug called Melphalan to wipe out the remaining, stubborn myeloma cells hiding in your body. The standard conditioning dose is 200 mg/m$^2$ (often referred to as MEL200). If your kidneys are severely impaired (creatinine clearance < 30 mL/min), your doctor will safely reduce the dose to 140 mg/m$^2$ to protect your body.
(4) The Greenhouse Phase (Recovery and Engraftment) About 1 to 2 days after the "deep clean", your frozen stem cells are safely thawed and returned to you through a simple IV infusion. Over the next 2 weeks, these cells will settle into your bone marrow and begin growing fresh, healthy blood cells—a process known as "engraftment". You will spend about 2 to 3 weeks in the hospital or an outpatient clinic being closely monitored. Because your immune system is temporarily wiped out, you must practice strict infection prevention: frequent hand washing, avoiding crowds, and immediately reporting any fever over 100.4°F to your healthcare team. It is completely normal to feel significant fatigue and weakness for 1 to 3 months, and you can expect to take 3 to 6 months off from work to fully recover. Since your immune system is brand new, your doctor will also have you re-vaccinated with inactivated vaccines starting 6 to 12 months post-transplant (including 3 doses of an mRNA SARS-CoV-2 vaccine starting 3 months post-ASCT).
(5) The Reward (Efficacy and PFS Benefits) Why do we go through this process? Because high-dose chemotherapy combined with ASCT continues to show a significant survival benefit over standard chemotherapy alone. It remains the standard of care for eligible patients because it offers the absolute best chance for a deep, long-lasting progression-free survival (PFS) and, in many cases, an overall survival advantage. Modern therapies ensure that the majority of patients achieve a Very Good Partial Response (VGPR) or better (exceeding 50%) even before the transplant begins, setting the stage for an excellent outcome.
(6) Alternate Paths (If you are transplant-ineligible) If you and your doctor decide that ASCT is too risky for your body, there is still an excellent, highly effective path forward. You will safely skip the transplant and simply continue your initial therapy for a longer period. For instance, you might receive about 9 cycles of a powerful combination like Daratumumab with Bortezomib, Lenalidomide, and Dexamethasone (Dara-VRd). If you are older or frail, your doctor may suggest a gentler regimen like Daratumumab with Lenalidomide and Dexamethasone (Dara-Rd). Afterwards, you will transition directly into a daily maintenance pill to keep the myeloma asleep for the long term.

The above content is sourced from the following references

First Line Treatment of Newly Diagnosed Transplant Eligible Multiple Myeloma
Multiple Myeloma Research Foundation Patient Toolkit
Mayo Stratification for Myeloma And Risk-adapted Therapy
EHA-EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma

Your share could light up hope for another patient 💛

FAQs

What is an autologous stem cell transplant?: An autologous transplant uses your own healthy stem cells after a high-dose chemotherapy reboot of the immune system. It is more like a specialized blood transfusion than a surgery. The aim is the deepest, longest-lasting remission possible.
Who can have a transplant?: Eligibility is based on overall health, fitness, and organ function, not just your age. Fit patients up to 70, and sometimes older adults in good shape, are routinely considered. Kidney impairment, including dialysis, does not automatically rule you out. Severe advanced heart or lung disease or an active infection is usually why a transplant is advised against.
How are stem cells collected?: After 3 to 6 cycles of initial treatment, ideally around cycle 4, you receive shots that move stem cells into the bloodstream. A machine then separates those cells from your blood over 3 to 4 hours across 1 to 5 days. Teams try to collect enough cells for one transplant and, if possible, a second course stored for later.
What happens during the transplant itself?: You receive high-dose melphalan to wipe out remaining myeloma cells, usually 200 mg per square meter, or 140 mg per square meter if the kidneys are severely impaired. One to two days later, your frozen stem cells are thawed and given back through an IV. They settle in the bone marrow over about 2 weeks, a process called engraftment.
How long does recovery take?: You typically spend 2 to 3 weeks in the hospital or clinic because your immune system is temporarily wiped out. Significant fatigue for 1 to 3 months is normal, and many people take 3 to 6 months off work. Inactivated vaccines, including mRNA COVID-19 shots starting about 3 months later, are restarted during recovery.
What if I am not eligible for a transplant?: You can skip the transplant and continue first-line therapy for a longer stretch, such as about 9 cycles of daratumumab with bortezomib, lenalidomide, and dexamethasone. Older or frailer patients may use a gentler combination of daratumumab, lenalidomide, and dexamethasone. After that, a daily maintenance pill is used to keep the myeloma asleep.

References used for this guide

Sincere thanks to the following authoritative institutions
for their academic support:

Lighting the hope of survival
for myeloma patients globally

Disclaimer: All disease knowledge, guideline interpretations, and treatment processes provided on this site are for learning and reference only, and do not constitute any medical advice or professional diagnosis. The condition of each patient is unique. For specific treatment plans and medication decisions, please be sure to follow the guidance of your attending physician or professional medical team.

This article is reviewed and published by the CMDN Editorial Team

Last updated: 2026-07-30

Get Support